Gold prices steady as traders assess Fed rate outlook after soft US data
NEW YORK - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical aesthetics company with a market capitalization of approximately $960 million, announced today the appointment of Peter Caldini as the new Chief Executive Officer, effective immediately. Caldini, who has been serving as Interim CEO since March 1 following the retirement of founder Juan José Chacón-Quirós, brings a wealth of experience from his previous leadership roles in healthcare and consumer companies.
Chairman of the Board, Nick Lewin, expressed confidence in Caldini’s capabilities, emphasizing the importance of his operational, commercial, and financial expertise in driving the company towards its financial goals. Lewin highlighted the company’s commitment to becoming EBITDA positive in 2025 and cash flow positive in 2026. According to InvestingPro data, the company currently reports negative EBITDA of $43.15 million, though its strong current ratio of 3.56 indicates solid short-term financial stability.
Caldini, in his remarks, expressed his honor in leading the company and pointed to Establishment Labs’ innovative contributions to breast aesthetics and reconstruction. He underscored the company’s strong market position and the potential for expansion, particularly with upcoming product launches in the United States. InvestingPro analysis reveals the company’s stock has shown significant momentum with an 8.8% return over the past week, despite experiencing high price volatility. Subscribers can access 8 additional ProTips and comprehensive financial analysis in the Pro Research Report.
Prior to joining Establishment Labs, Caldini held CEO positions at Acreage Holdings, Inc. and Bespoke Capital Acquisition Corp. His experience also includes significant roles at Pfizer Consumer Healthcare and Bayer Consumer Healthcare. Caldini’s educational background includes degrees from Boston University, Northeastern University, and SDA Bocconi.
Establishment Labs is known for its Motiva® devices, with over four million units delivered since 2010, and a suite of products that includes Mia Femtech®, Preservé™, and the Motiva Flora® tissue expander. The company maintains a strong focus on innovation, supported by extensive patent applications and scientific studies.
The information in this article is based on a press release statement from Establishment Labs Holdings Inc.
In other recent news, Establishment Labs Holdings Inc. reported several significant developments. Mizuho Securities maintained an Outperform rating on the company, though it adjusted its price target from $70 to $58 following the fourth quarter earnings report. The report highlighted fourth quarter sales of approximately $3.3 million for the Motiva breast implants, with a projected increase to $5.5 million in the first quarter. The company has set a fiscal year 2025 sales target for Motiva in the U.S. at $35 million, while overall sales guidance is anticipated to range between $205 million and $210 million.
TD Cowen also maintained a Buy rating for Establishment Labs, revising its price target to $60 from $75, citing strong early launch trends of the Motiva implants in the U.S. Needham initiated coverage with a Hold rating, noting the U.S. launch of Motiva as a key growth catalyst, though expressing concerns over international business performance due to trade tensions. Despite trade concerns, Mizuho highlighted a potential buying opportunity due to recent price corrections, maintaining confidence in the company’s strategic position. Establishment Labs is expected to navigate new tariff policies effectively, with TD Cowen noting minimal financial impact from tariffs due to the company’s operational base in Costa Rica.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.